Adult AML patients (n = 441) displayed the following rearrangements: KMT2A-PTD (n = 113; 25.6%), MLLT3 (n = 108; 24.5%), ELL (n = 51; 11.6%), AFDN (n = 45; 10.2%), MLLT10 (n = 44; 10.0%), MLLT1 (n = 16; 3.6%), EPS15 (n = 7; 1.6%), AFF1 (n = 5; 1.1%) and 25 other KMT2A rearrangements. This evidence concerns the gene KMT2A and acute myeloid leukemia.